Lifecore Biomedical, Inc. (LFCR)
NASDAQ: LFCR · Real-Time Price · USD
6.35
+0.18 (2.92%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Lifecore Biomedical Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Lifecore Biomedical stock have an average target of 8.00, with a low estimate of 6.00 and a high estimate of 10. The average target predicts an increase of 25.98% from the current stock price of 6.35.
Analyst Consensus: Buy
* Price targets were last updated on Jan 3, 2025.
Analyst Ratings
The average analyst rating for Lifecore Biomedical stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 2 | 2 | 3 | 3 | 3 | 3 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Stephens & Co. | Stephens & Co. | Hold Reiterates $6 | Hold | Reiterates | $6 | -5.51% | Jan 3, 2025 |
Craig-Hallum | Craig-Hallum | Strong Buy Maintains $8 → $10 | Strong Buy | Maintains | $8 → $10 | +57.48% | Nov 22, 2024 |
Craig-Hallum | Craig-Hallum | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +25.98% | Sep 5, 2024 |
Barrington Research | Barrington Research | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Aug 28, 2024 |
Barrington Research | Barrington Research | Buy Maintains $11 → $10 | Buy | Maintains | $11 → $10 | +57.48% | Sep 1, 2023 |
Financial Forecast
Revenue This Year
130.27M
from 128.26M
Increased by 1.57%
Revenue Next Year
135.46M
from 130.27M
Increased by 3.98%
EPS This Year
-1.36
from 0.32
EPS Next Year
-0.71
from -1.36
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|
High | 134.8M | 143.6M | 165.1M | |
Avg | 130.3M | 135.5M | 155.5M | |
Low | 124.5M | 126.3M | 144.7M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|
High | 5.1% | 10.2% | 21.9% | |
Avg | 1.6% | 4.0% | 14.8% | |
Low | -2.9% | -3.1% | 6.9% |
EPS Forecast
EPS | 2025 | 2026 | 2027 |
---|---|---|---|
High | -1.39 | -0.64 | -0.42 |
Avg | -1.36 | -0.71 | -0.41 |
Low | -1.31 | -0.77 | -0.39 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.